If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 15
A Randomized Phase III Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
This study is being done to answer the following question:
Is it necessary to continue the study drug zanubrutinib once remission has been retained?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your mantle cell lymphoma. The usual approach is defined as care most people get for previously untreated mantle cell lymphoma.
Is it necessary to continue the study drug zanubrutinib once remission has been retained?
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your mantle cell lymphoma. The usual approach is defined as care most people get for previously untreated mantle cell lymphoma.
Protocol No
ALLIANCE-A052101
Categories
A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
This project is being done to learn more about the safety and efficacy of Acalabrutinib, when given in combination with Venetoclax and Rituximab (AVR), to participants with previously untreated mantle cell lymphoma (MCL).
Protocol No
AZ-D822GC00001-TRAVERSE
Categories
An Open-Label, Multi-Center, Single-Arm Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
This project is being done to evaluate the safety and tolerability of glofitamab-polatuzumab-R-CHP in patients newly diagnosed DLBCL and determine if a blood test that measures MRD can identify patients most likely to benefit from this regimen.
Protocol No
DFCI-22-606
Categories
A Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Epcoritamab and Rituximab for Patients with Untreated Follicular Lymphoma (FL)
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with FL and who have not received other treatments for their lymphoma
Protocol No
DFCI-22-702
Categories
A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B-Cell Lymphoma
Split-Dose R-CHOP for Older Adults with DLBCL
Protocol No
WON-SHAH-UW18131-SPLIT-RCHOP
Categories
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
Phase II, Single-Arm, Open-Label, Multicenter Study Evaluating the Efficacy of Adjunctive Zanubrutinib and CAR T-Cell Therapy in Aggressive B-cell Non-Hodgkins Lymphoma
Phase II Study Evaluating Adjunctive Zanubrutinib and CAR T-cell therapy in Aggressive B-cell Non-Hodgkins Lymphoma
Protocol No
NU-20H09-NHL
Categories
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Protocol No
C4THERAPEUTICS-CFT7455-1101
Categories
A Multicenter, Open-Label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-Cell Malignancies
This project is being done to test the safety of zilovertamab vedotin when given alone or
with nemtabrutinib, and to see how well zilovertamab vedotin works when given alone or with nemtabrutinib to treat B-cell cancers.
with nemtabrutinib, and to see how well zilovertamab vedotin works when given alone or with nemtabrutinib to treat B-cell cancers.
Protocol No
MERCK-MK2140-006-CLL-NHL
Categories
A Phase Ib, Open-Label, Multicenter, Single Arm Study Evaluating the Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Patients with Relapsed/Refractory
A Phase Ib Study Evaluating Glofitamab In Patients With Relapsed/Refractory Transplant Eligible Diffuse B-Cell Lymphoma
Protocol No
HOFFMANNLAROCHE-GO43693
Categories